Akorn Plunges After Judge Backs Fresenius Exit From Deal

(Bloomberg) -- Fresenius SE had proper grounds for canceling a $4.3 billion buyout of rival drugmaker Akorn Inc. and doesn’t need to consummate the deal, a judge said in a ruling that comes as a bl...
BQ Install

Bloomberg Quint

Add BloombergQuint App to Home screen.